Key result
Novel adipokines and adipose-derived extracellular vesicles emerge as potential therapeutic targets for metabolic liver disease.
Why the study?
Under conditions such as obesity and diabetes, dysregulation of adipokines and adipose-derived extracellular vesicles can cause liver diseases, and clarifying their actions could identify novel therapeutic targets or biomarkers.
Clarifying the action of novel adipokines and adipose-derived extracellular vesicles on the liver may help identify new therapeutic targets or biomarkers for metabolic and liver diseases.
May aid biomarker discovery in metabolic liver disease; leaves open therapeutic targeting pending interventional studies.
Adipose tissues (AT) are an important endocrine organ that secretes various functional adipokines, peptides, non-coding RNAs, and acts on AT themselves or other distant tissues or organs through autocrine, paracrine, or endocrine manners. An accumulating body of evidence has suggested that many adipokines play an important role in liver metabolism. Besides the traditional adipokines such as adiponectin and leptin, many novel adipokines have recently been identified to have regulatory effects on the liver. Additionally, AT can produce extracellular vesicles (EVs) that act on peripheral tissues. However, under pathological conditions, such as obesity and diabetes, dysregulation of adipokines is associated with functional changes in AT, which may cause liver diseases. In this review, we focus on the newly discovered adipokines and EVs secreted by AT and highlight their actions on the liver under the context of obesity, nonalcoholic fatty liver diseases (NAFLD), and some other liver diseases. Clarifying the action of adipokines and adipose tissue-derived EVs on the liver would help to identify novel therapeutic targets or biomarkers for metabolic diseases.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2024) conducted a review in Liver diseases (obesity, NAFLD). Novel adipokines and adipose-derived extracellular vesicles (ADEVs) was evaluated. Novel adipokines and adipose tissue-derived extracellular vesicles play important regulatory roles in liver metabolism and may serve as therapeutic targets or biomarkers for metabolic liver diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: